Skip to main content
Premium Trial:

Request an Annual Quote

IMDx to Develop Tests on Abbott's m2000 Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IMDx reported on Thursday that it has entered into an agreement with Abbott to design, develop, and manufacture assays using Abbott's FDA-approved m2000 platform.

Privately held IMDx will also bring the assays through the regulatory process.

Financial and other terms of the multi-year deal were not disclosed.

The tests covered by the agreement include assays for Clostridium difficile, vancomycin-resistant Enterococci; Group B Streptococci; Influenza A/Influenza B, and Herpes simplex virus types 1 and 2. Two other tests, for determining the viral load for Epstein-Barr virus and for BK virus, will be commercialized outside the US, Cambridge, Mass.-based IMDx said.

The company uses its proprietary bioinformatics process to create its tests, ensuring products that are optimized and in silico verified, it said.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.